These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 12363467)

  • 1. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients.
    Romeo M; Chauffaille Mde L; Silva MR; Bahia DM; Kerbauy J
    Leuk Res; 2002 Nov; 26(11):993-6. PubMed ID: 12363467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype.
    Rigolin GM; Bigoni R; Milani R; Cavazzini F; Roberti MG; Bardi A; Agostini P; Della Porta M; Tieghi A; Piva N; Cuneo A; Castoldi G
    Leukemia; 2001 Dec; 15(12):1841-7. PubMed ID: 11753603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.
    Beyer V; Castagné C; Mühlematter D; Parlier V; Gmür J; Hess U; Kovacsovics T; Meyer-Monard S; Tichelli A; Tobler A; Jacky E; Schanz U; Bargetzi M; Hagemeijer A; de Witte T; van Melle G; Jotterand M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):29-41. PubMed ID: 15193439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
    Cai Y; Qin YW; Wang C; Yang J; Yan SK
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):6-10. PubMed ID: 17649717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
    Pitchford CW; Hettinga AC; Reichard KK
    Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).
    Makishima H; Rataul M; Gondek LP; Huh J; Cook JR; Theil KS; Sekeres MA; Kuczkowski E; O'Keefe C; Maciejewski JP
    Leuk Res; 2010 Apr; 34(4):447-53. PubMed ID: 19758696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of common chromosome abnormalities in myelodysplastic syndrome with a panel fluorescence in situ hybridization].
    Shen Y; Xue Y; Li J; Pan J; Wu Y; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):160-3. PubMed ID: 12673589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chromosomal aberrations in myelodysplastic syndrome].
    Ol'shanskaia IuV; Domracheva EV; Udovichenko AI; Vodinskaia LA; Zakharova AV; Parovichnikova EN; Tsvetaeva NV; Mikhaĭlova EA; Glasko EN; Kolosova LIu; Kokhno AN; Tikhonova LIu; Shitareva TV; Smirnova EA; Alimova GA; Shirin AD; Vinogradova OIu; Khoroshko ND; Savchenko VG
    Ter Arkh; 2005; 77(7):27-33. PubMed ID: 16116905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.
    Chen L; Li J; Zhu Y; Qiu H; Pan J; Wang R; Qian S; Xu W; Xue Y
    Exp Oncol; 2007 Dec; 29(4):299-303. PubMed ID: 18199987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
    Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
    J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized fluorescence in situ hybridization testing based on an appropriate panel of probes more effectively identifies common cytogenetic abnormalities in myelodysplastic syndromes than conventional cytogenetic analysis: a multicenter prospective study of 2302 patients in China.
    Lai YY; Huang XJ; Li J; Zou P; Xu ZF; Sun H; Shao ZH; Zhou DB; Chen FP; Liu ZG; Zhu HL; Wu DP; Wang C; Zhang Y; Li Y; Hou M; Du X; Wang X; Li W; Lai YR; Zhou J; Zhou YH; Fang MY; Qiu L; Wang XM; Zhang GS; Jiang M; Liang YM; Zhang LS; Chen XQ; Bai H; Lin JY
    Leuk Res; 2015 May; 39(5):530-5. PubMed ID: 25823643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
    Göhring G; Giagounidis A; Büsche G; Hofmann W; Kreipe HH; Fenaux P; Hellström-Lindberg E; Schlegelberger B
    Haematologica; 2011 Feb; 96(2):319-22. PubMed ID: 21109690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities.
    Gurney M; Patnaik MM; Hanson CA; Litzow MR; Al-Kali A; Ketterling RP; Tefferi A; Gangat N
    Br J Haematol; 2017 Jul; 178(1):57-60. PubMed ID: 28419466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytogenetic abnormalities of 50 MDS patients by FISH detection and conventional karyotype analysis].
    Gao DG; Li BT; Zhou LN; Chen H; Zhang B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1190-4. PubMed ID: 24156432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.